Table 2 Response*(%) at 3 and 6 months, stratified by certolizumab pegol level at 3 months
|  | Overall | CZP < 20 mg/L | CZP 20–39.9 mg/L | CZP ≥ 40 mg/L | OR** (95% CI) | P** |
|---|---|---|---|---|---|---|
|  | Responders* after 3 months | |||||
All patients (n = 245) | 53% | 35% | 65% | 49% | 2.3 (1.2–4.5) | < 0.05 |
axSpA (n = 110) | 40% | 18% | 53% | 37% | 3.4 (1.0–11.1) | < 0.05 |
RA (n = 81) | 61% | 44% | 74% | 55% | 1.5 (0.5–5.1) | 0.48 |
PsA (n = 54) | 69% | 47% | 77% | 77% | 4.3 (1.0–17.9) | < 0.05 |
|  | Responders* after 6 months | |||||
All patients (n = 245) | 52% | 38% | 63% | 48% | 1.9 (1.0–3.5) | 0.05 |
axSpA (n = 110) | 40% | 18% | 55% | 34% | 3.3 (1.0–10.8) | < 0.05 |
RA (n = 81) | 57% | 50% | 62% | 55% | 1.1 (0.3–3.4) | 0.92 |
PsA (n = 54) | 70% | 53% | 77% | 70% | 3.3 (0.8–13.3) | 0.09 |